Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report

BACKGROUND: The advent of tyrosine kinase inhibitors (TKIs) has changed the treatment of RAI refractory, unresectable recurrent differentiated thyroid cancer (DTC), which was formerly treated with multidisciplinary remedies. CASE PRESENTATION: Here we describe the case of a 64-year-old woman who und...

Descripción completa

Detalles Bibliográficos
Autores principales: Tori, Masayuki, Shimo, Toshirou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022486/
https://www.ncbi.nlm.nih.gov/pubmed/29954369
http://dx.doi.org/10.1186/s12885-018-4612-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022486/
https://www.ncbi.nlm.nih.gov/pubmed/29954369
http://dx.doi.org/10.1186/s12885-018-4612-2

Ejemplares similares